Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Private Capital To Enter High-End Health Care Market

This article was originally published in PharmAsia News

Executive Summary

San Paulo Mans Hospital, the first patient membership hospital in Beijing, has commenced operation, marking the beginning of private capital flowing into China's high-end health care market. Most analysts hold optimistic views about the development and point out that private investment in luxury health care will meet the requirements of a growing high-income market. As the government puts priority on supporting basic health care and providing insurance to its disadvantaged population, the latest involvement by the private sector frees it to focus on formulating regulations and standards, setting admittance thresholds, enhancing market supervision, providing reasonable subsidies and creating a fair competition environment for private capital. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel